The DOI matches its Crossref record; 146 of the 146 references it cites were found in a registry or an index.
Strategies toward rheumatoid arthritis therapy; the old and the new
Abstract
Currently, medications used to treat rheumatoid arthritis (RA) are glucocorticoids (GCs) and nonsteroidal anti‐inflammatory drugs (NSAIDs), predominantly used for controlling the pain and inflammation, disease‐modifying antirheumatic drugs (DMARDs), administered as first‐line medication for newly diagnosed RA cases, and biological therapies, used to target and inhibit specific molecules of the immune and inflammatory responses. NSAIDs and other GCs are effective in alleviating the pain, inflammation, and stiffness due to RA. DMARDs that are used for RA therapy are hydroxychloroquine, methotrexate, leflunomide, and sulfasalazine. The biological therapies, on the contrary, are chimeric anti‐CD20 monoclonal antibody, rituximab, inhibitors of tumor necrosis factor‐α (TNF‐α) like etanercept, infliximab, and adalimumab, a recombinant inhibitor of interleukin‐1 (IL‐1), anakinra, and costimulation blocker, abatacept. Moreover, newly under evaluation biological therapies include new TNF‐α inhibitors, JAK inhibitors, anti‐interleukin‐6‐receptor monoclonal antibodies (mABs), and antibodies against vital molecules involved in the survival and development of functional B cells. The new strategies to treat RA has improved the course of the disease and most of the patients are successful in remission of the clinical manifestations if the diagnosis of the disease occur early. The probability of remission increase if the diagnosis happens rapidly and treat‐to‐target approach are implemented. In this review article, we have attempted to go through the treatment strategies for RA therapy both the routine ones and those which have been developed over the past few years and currently under investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., et al. (2000) · JAMA · doi:10.1001/jama.284.10.1247 · Cited by 3,154
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs
Wolfe, M. M., Lichtenstein, D. R., & Singh, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906173402407 · Cited by 1,956
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., Genovese, M. C., Wasko, M. C., Moreland, L. W., Weaver, A. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432201 · Cited by 1,730
Grigor, C., Capell, H., Stirling, A., McMahon, A. D., Lock, P., Vallance, R., Porter, D., & Kincaid, W. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16676-2 · Cited by 1,435
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Keystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A., & Chartash, E. K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20217 · Cited by 1,172
St. Clair, E. W., van der Heijde, D. M. F. M., Smolen, J. S., Maini, R. N., Bathon, J. M., Emery, P., Keystone, E., Schiff, M., Kalden, J. R., Wang, B., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20568 · Cited by 1,143
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study
Choi, H. K., Hernán, M. A., Seeger, J. D., Robins, J. M., & Wolfe, F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08213-2 · Cited by 1,127
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Kremer, J. M., Westhovens, R., Leon, M., Di Giorgio, E., Alten, R., Steinfeld, S., Russell, A., Dougados, M., Emery, P., Nuamah, I. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035075 · Cited by 1,058
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α
Elliott, M. J., Maini, R. N., Feldmann, M., Long‐Fox, A., Charles, P., Katsikis, P., Brennan, F. M., Walker, J., Bijl, H., Ghrayeb, J., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780361206 · Cited by 1,038
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
Bresnihan, B., Alvaro-Gracia, J. M., Cobby, M., Doherty, M., Domljan, Z., Emery, P., Nuki, G., Pavelka, K., Rau, R., Rozman, B., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199812)41:12<2196::aid-art15>3.0.co;2-2 · Cited by 981
Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E., & Beenhouwer, D. O. (2004) · Clinical Infectious Diseases · doi:10.1086/383317 · Cited by 977
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Jørgensen, K. K., Olsen, I. C., Goll, G. L., Lorentzen, M., Bolstad, N., Haavardsholm, E. A., Lundin, K. E. A., Mørk, C., Jahnsen, J., Kvien, T. K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30068-5 · Cited by 818
Sharief, M. K., & Hentges, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108153250704 · Cited by 809
Anti-inflammatory drugs and their mechanism of action
Vane, J. R., & Botting, R. M. (1998) · Inflammation Research · doi:10.1007/s000110050284 · Cited by 798
Smolen, J. S., Kalden, J. R., Scott, D. L., Rozman, B., Kvien, T. K., Larsen, A., Loew-Friedrich, I., Oed, C., & Rosenburg, R. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09403-3 · Cited by 771
Moving towards individualized medicine with pharmacogenomics
Evans, W. E., & Relling, M. V. (2004) · Nature · doi:10.1038/nature02626 · Cited by 768
Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate
Strand, V. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.21.2542 · Cited by 754
Horai, R., Saijo, S., Tanioka, H., Nakae, S., Sudo, K., Okahara, A., Ikuse, T., Asano, M., & Iwakura, Y. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.313 · Cited by 749
Cronstein, B. N., Naime, D., & Ostad, E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116884 · Cited by 679
Cohen, S., Hurd, E., Cush, J., Schiff, M., Weinblatt, M. E., Moreland, L. W., Kremer, J., Bear, M. B., Rich, W. J., & McCabe, D. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10141 · Cited by 638
New Drugs for Rheumatoid Arthritis
Olsen, N. J., & Stein, C. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032906 · Cited by 626
Therapeutic Strategies for Rheumatoid Arthritis
O'Dell, J. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040226 · Cited by 588
Augello, A., Tasso, R., Negrini, S. M., Cancedda, R., & Pennesi, G. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22511 · Cited by 587
Verstappen, S. M. M., Jacobs, J. W. G., van der Veen, M. J., Heurkens, A. H. M., Schenk, Y., ter Borg, E. J., Blaauw, A. A. M., & Bijlsma, J. W. J. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.071092 · Cited by 566
Emery, P., Zeidler, H., Kvien, T. K., Guslandi, M., Naudin, R., Stead, H., Verburg, K. M., Isakson, P. C., Hubbard, R. C., & Geis, G. S. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02332-6 · Cited by 543
Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis
Cronstein, B. N. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.3 · Cited by 535
Genovese, M. C., Cohen, S., Moreland, L., Lium, D., Robbins, S., Newmark, R., Bekker, P., & for the 20000223 Study Group (2004) · Arthritis & Rheumatism · doi:10.1002/art.20221 · Cited by 532
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
Ray, W. A., Stein, C. M., Daugherty, J. R., Hall, K., Arbogast, P. G., & Griffin, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11131-7 · Cited by 503
Furst, D. E., Schiff, M. H., Fleischmann, R., Strand, V., Birbara, C. A., Compagnone, D., Fischkoff, S. A., & Chartash, E. (2003) · PubMed · Cited by 495
González, M. A., Gonzalez‐Rey, E., Rico, L., Büscher, D., & Delgado, M. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24405 · Cited by 489
Emery, P., Breedveld, F. C., Lemmel, E. M., Kaltwasser, J. P., Dawes, P. T., Gömör, B., Van den Bosch, F., Nordström, D., Bjørneboe, O., Dahl, R., et al. (2000) · Rheumatology · doi:10.1093/rheumatology/39.6.655 · Cited by 472
Prevention of NSAID-induced gastroduodenal ulcers
Rostom, A., Dube, C., Wells, G. A., Tugwell, P., Welch, V., Jolicoeur, E., McGowan, J., Lanas, A., Rushton, E., & Shukla, T. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002296 · Cited by 470
Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
Cross, A. H., Stark, J. L., Lauber, J., Ramsbottom, M. J., & Lyons, J.-A. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.06.029 · Cited by 454
The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting
Malmström, V., Catrina, A. I., & Klareskog, L. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.124 · Cited by 451
Kremer, J. M., Dougados, M., Emery, P., Durez, P., Sibilia, J., Shergy, W., Steinfeld, S., Tindall, E., Becker, J., Li, T., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21201 · Cited by 444
The use of single-nucleotide polymorphism maps in pharmacogenomics
McCarthy, J. J., & Hilfiker, R. (2000) · Nature Biotechnology · doi:10.1038/75360 · Cited by 434
Fleischmann, R., Schiff, M., van der Heijde, D., Ramos‐Remus, C., Spindler, A., Stanislav, M., Zerbini, C. A. F., Gurbuz, S., Dickson, C., de Bono, S., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39953 · Cited by 427
Gonzalez-Rey, E., Gonzalez, M. A., Varela, N., O'Valle, F., Hernandez-Cortes, P., Rico, L., Büscher, D., & Delgado, M. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101881 · Cited by 426
Cohen, S. B., Tanaka, Y., Mariette, X., Curtis, J. R., Lee, E. B., Nash, P., Winthrop, K. L., Charles-Schoeman, C., Thirunavukkarasu, K., DeMasi, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210457 · Cited by 393
Matherly, L. H., & Goldman, I. D. (2003) · Vitamins & Hormones · doi:10.1016/s0083-6729(03)01012-4 · Cited by 386
Anker, S. D., & Coats, A. J. S. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00470-9 · Cited by 367
Glucocorticoids in the treatment of rheumatic diseases: An update on the mechanisms of action
Buttgereit, F., Straub, R. H., Wehling, M., & Burmester, G. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20583 · Cited by 367
The safety and efficacy of the use of methotrexate in long‐term therapy for rheumatoid arthritis
Kremer, J. M., & Lee, J. K. (1986) · Arthritis & Rheumatism · doi:10.1002/art.1780290702 · Cited by 360
Ramiro, S., Sepriano, A., Chatzidionysiou, K., Nam, J. L., Smolen, J. S., van der Heijde, D., Dougados, M., van Vollenhoven, R., Bijlsma, J. W., Burmester, G. R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210708 · Cited by 358
Primer on the Rheumatic Diseases
Ehrlich, G. E. (2008) · JAMA · doi:10.1001/jama.299.10.1195-a · Cited by 356
Kremer, J. M., Genovese, M. C., Cannon, G. W., Caldwell, J. R., Cush, J. J., Furst, D. E., Luggen, M. E., Keystone, E., Weisman, M. H., Bensen, W. M., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-9-200211050-00007 · Cited by 353
Nile, C. J., Read, R. C., Akil, M., Duff, G. W., & Wilson, A. G. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23758 · Cited by 338
DNA hypomethylation in rheumatoid arthritis synovial fibroblasts
Karouzakis, E., Gay, R. E., Michel, B. A., Gay, S., & Neidhart, M. (2009) · Arthritis & Rheumatism · doi:10.1002/art.25018 · Cited by 308
Weinblatt, M. E., Kremer, J. M., Coblyn, J. S., Maier, A. L., Helfgott, S. M., Morrell, M., Byrne, V. M., Kaymakcian, M. V., & Strand, V. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199907)42:7<1322::aid-anr4>3.0.co;2-p · Cited by 286
Curtis, J. R., Xie, F., Yun, H., Bernatsky, S., & Winthrop, K. L. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209131 · Cited by 285
Keystone, E. C., Schiff, M. H., Kremer, J. M., Kafka, S., Lovy, M., DeVries, T., & Burge, D. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20019 · Cited by 284
Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components
Aletaha, D., Smolen, J., & Ward, M. M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22052 · Cited by 276
Short, B., Brouard, N., Occhiodoro-Scott, T., Ramakrishnan, A., & Simmons, P. J. (2003) · Archives of Medical Research · doi:10.1016/j.arcmed.2003.09.007 · Cited by 269
Treatment of rheumatoid arthritis
Gaffo, A., Saag, K. G., & Curtis, J. R. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050514 · Cited by 266
Strangfeld, A., Hierse, F., Rau, R., Burmester, G.-R., Krummel-Lorenz, B., Demary, W., Listing, J., & Zink, A. (2010) · Arthritis Research & Therapy · doi:10.1186/ar2904 · Cited by 264
The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine
Mavrikakis, I., Sfikakis, P. P., Mavrikakis, E., Rougas, K., Nikolaou, A., Kostopoulos, C., & Mavrikakis, M. (2003) · Ophthalmology · doi:10.1016/s0161-6420(03)00409-3 · Cited by 256
Clinical Pharmacokinetics of Leflunomide
Rozman, B. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241060-00003 · Cited by 250
Felson, D. T., Anderson, J. J., & Meenan, R. F. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780351003 · Cited by 230
Quéméneur, L., Gerland, L.-M., Flacher, M., Ffrench, M., Revillard, J.-P., & Genestier, L. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.4986 · Cited by 229
van Walsem, A., Pandhi, S., Nixon, R. M., Guyot, P., Karabis, A., & Moore, R. A. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0554-0 · Cited by 222
Montesinos, M. C., Desai, A., Delano, D., Chen, J., Fink, J. S., Jacobson, M. A., & Cronstein, B. N. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10712 · Cited by 213
Grabiec, A. M., Korchynskyi, O., Tak, P. P., & Reedquist, K. A. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.154211 · Cited by 211
Huber, L. C., Brock, M., Hemmatazad, H., Giger, O. T., Moritz, F., Trenkmann, M., Distler, J. H. W., Gay, R. E., Kolling, C., Moch, H., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22512 · Cited by 211
Dervieux, T., Greenstein, N., & Kremer, J. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22129 · Cited by 201
The immunomodulatory function of mesenchymal stem cells: mode of action and pathways
Uccelli, A., & de Rosbo, N. K. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12815 · Cited by 200
The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites
Gadangi, P., Longaker, M., Naime, D., Levin, R. I., Recht, P. A., Montesinos, M. C., Buckley, M. T., Carlin, G., & Cronstein, B. N. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.5.1937 · Cited by 196
Guidelines for monitoring drug therapy in rheumatoid arthritis
American College of Rheumatology AD Hoc Committee on Clinical Guidelines (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390503 · Cited by 193
Inhibition of p38: Has the fat lady sung?
Genovese, M. C. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24264 · Cited by 192
Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)
Buttgereit, F., Mehta, D., Kirwan, J., Szechinski, J., Boers, M., Alten, R. E., Supronik, J., Szombati, I., Romer, U., Witte, S., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201067 · Cited by 191
Mercer, L. K., Askling, J., Raaschou, P., Dixon, W. G., Dreyer, L., Hetland, M. L., Strangfeld, A., Zink, A., Mariette, X., Finckh, A., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209285 · Cited by 188
Phillips, D. C., Woollard, K. J., & Griffiths, H. R. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705054 · Cited by 183
Simms, R. W., Kwoh, C. K., Anderson, L. G., Erlandson, D. M., Greene, J. M., Kelleher, M. E., O’Dell, J. R., Partridge, A. J., Roberts, W. N., Robbins, M. L., et al. (1996) · PubMed · Cited by 182
Klarenbeek, N. B., Güler-Yüksel, M., van der Kooij, S. M., Han, K. H., Ronday, H. K., Kerstens, P. J. S. M., Seys, P. E. H., Huizinga, T. W. J., Dijkmans, B. A. C., & Allaart, C. F. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.141234 · Cited by 180
White, W. B., Faich, G., Borer, J. S., & Makuch, R. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00659-3 · Cited by 174
G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis
Cornish, A. L., Campbell, I. K., McKenzie, B. S., Chatfield, S., & Wicks, I. P. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.178 · Cited by 159
The Pharmacokinetics of Etanercept in Healthy Volunteers
Korth-Bradley, J. M., Rubin, A. S., Hanna, R. K., et al. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19126 · Cited by 155
Gillespie, J., Savic, S., Wong, C. H., Hempshall, A., Inman, M. W., Emery, P., Grigg, R., & McDermott, M. (2011) · Arthritis & Rheumatism · doi:10.1002/art.33382 · Cited by 150
LISSE, J. R., Perlman, M., Johansson, G. S., Shoemaker, J. R., Schechtman, J., Skalky, C. S., Dixon, M. E., Polis, A. B., Mollen, A., Geba, G. P., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-7-200310070-00005 · Cited by 149
Thompson, A., Rieder, S. W., & Pope, J. E. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30310 · Cited by 147
Janus kinase inhibitors for rheumatoid arthritis
Yamaoka, K. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.03.006 · Cited by 142
Rofecoxib (Vioxx) voluntarily withdrawn from market
Sibbald, B. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041606 · Cited by 141
Etiology and Pathogenesis of Rheumatoid Arthritis
McDuffie, F. C. (1971) · Orthopedic Clinics of North America · doi:10.1016/s0030-5898(20)32157-x · Cited by 139
APLAR rheumatoid arthritis treatment recommendations
Lau, C. S., Chia, F. L., Harrison, A. A., Hsieh, T., Jain, R., Jung, S. M., Kishimoto, M., Kumar, A., Leong, K. P., Li, Z., et al. (2015) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12754 · Cited by 132
Choo, Q., Ho, P. C., Tanaka, Y., & Lin, H. (2010) · Rheumatology · doi:10.1093/rheumatology/keq108 · Cited by 130
Weber, S. M., & Levitz, S. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.3.1534 · Cited by 129
Brodszky, V., Baji, P., Balogh, O., et al. (2014) · The European Journal of Health Economics · doi:10.1007/s10198-014-0595-3 · Cited by 129
Gøtzsche, P. C., & Johansen, H. (1998) · BMJ · doi:10.1136/bmj.316.7134.811 · Cited by 118
Patient and Physician Factors Associated With Adherence to Diabetes Medications
Schoenthaler, A., Schwartz, B. S., Wood, C., & Stewart, W. F. (2012) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721712440333 · Cited by 106
Smolen, J. S., Aletaha, D., Grisar, J. C., Stamm, T., & Sharp, J. T. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.114652 · Cited by 105
Major Histocompatibility Complex-Directed Susceptibility to Rheumatoid Arthritis
Nepom, G. T. (1998) · Advances in immunology · doi:10.1016/s0065-2776(08)60563-5 · Cited by 104
Hamdy, H., McKendry, R. J. R., Mierins, E., & Liver, J. A. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780300401 · Cited by 103
Epigenetic alterations underlying autoimmune diseases
Aslani, S., Mahmoudi, M., Karami, J., Jamshidi, A., Malekshahi, Z., & Nicknam, M. H. (2016) · Autoimmunity · doi:10.3109/08916934.2015.1134511 · Cited by 101
Self-citationPascual‐Ramos, V., Contreras-Yáñez, I., Villa, A. R., Cabiedes, J., & Rull‐Gabayet, M. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2620 · Cited by 97
Kremer, J. M. (1999) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(99)80034-1 · Cited by 93
Gabay, C., Riek, M., Scherer, A., & Finckh, A. (2015) · Lara D. Veeken · doi:10.1093/rheumatology/kev019 · Cited by 91
Liu, R., Li, X., Zhang, Z., Zhou, M., Sun, Y., Su, D., Feng, X., Gao, X., Shi, S., Chen, W., et al. (2015) · Scientific Reports · doi:10.1038/srep12777 · Cited by 91
Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: a meta-analysis
Ravindran, V. K., Rachapalli, S. M., & Choy, E. (2009) · Rheumatology · doi:10.1093/rheumatology/kep096 · Cited by 90
Interleukin-22 in human inflammatory diseases and viral infections
Shabgah, A. G., Navashenaq, J. G., Shabgah, O. G., Mohammadi, H., & Sahebkar, A. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.10.004 · Cited by 89
Self-citationInhibition of nuclear factor kappa B and induction of apoptosis in T‐lymphocytes by sulfasalazine
Liptay, S., Bachem, M. G., Häcker, G. A., Adler, G., Debatin, K., & Schmid, R. M. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702937 · Cited by 86
Aletaha, D., Alasti, F., & Smolen, J. S. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208324 · Cited by 85
Grabiec, A. M., Tak, P. P., & Reedquist, K. A. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2489 · Cited by 84
Combe, C., Tredree, R., & Schellekens, H. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.7.954 · Cited by 83
MacDonald, G. I. A., Augello, A., & Bari, C. D. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30474 · Cited by 78
López‐Santalla, M., Mancheño‐Corvo, P., Menta, R., López-Belmonte, J. L., DelaRosa, O., Bueren, J. A., Dalemans, W., Lombardo, E., & Garin, M. I. (2015) · Stem Cells · doi:10.1002/stem.2113 · Cited by 74
Aslani, S., Mahmoudi, M., Garshasbi, M., Jamshidi, A., Karami, J., & Nicknam, M. H. (2016) · Clinical Rheumatology · doi:10.1007/s10067-016-3403-x · Cited by 70
Self-citationSelective Cyclooxygenase-2 Inhibition and Cardiovascular Effects
Shaya, F. T. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.2.181 · Cited by 67
New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis
Mahmoudi, M., Aslani, S., Fadaei, R., & Jamshidi, A. (2017) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12999 · Cited by 67
Self-citationZhu, H. L., Deng, F., Mo, X., Qiu, Y., & Lei, S. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.25 · Cited by 62
Refractory Nephrotic Syndrome in Lupus Nephritis: Favorable Response to Indomethacin Therapy
Espinoza, L. R., Jara, L. J., Martínez-Osuna, P., Silveira, L. H., Cuellar, M. L., & Seleznick, M. J. (1993) · Lupus · doi:10.1177/096120339300200103 · Cited by 61
Teitsma, X. M., Marijnissen, A. C. A., Bijlsma, J. W. J., Lafeber, F. P. J. G., & Jacobs, J. W. G. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-1108-9 · Cited by 59
Implications of the noncoding RNAs in rheumatoid arthritis pathogenesis
Mousavi, M. J., Jamshidi, A., Chopra, A., Aslani, S., Akhlaghi, M., & Mahmoudi, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26911 · Cited by 58
Self-citationPharmacology of glucocorticoids in rheumatoid arthritis
Spies, C. M., Bijlsma, J. W. J., Burmester, G. R., & Buttgereit, F. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.02.001 · Cited by 56
Fifty Years of Experience with Cortisone Therapy in the Study and Treatment of Rheumatoid Arthritis
Neeck, G. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04199.x · Cited by 53
Karami, J., Mahmoudi, M., Amirzargar, A. A., Gharshasbi, M., Jamshidi, A., Aslani, S., & Nicknam, M. H. (2017) · Genes and Immunity · doi:10.1038/gene.2017.17 · Cited by 53
Self-citationSany, J., Kaiser, M. J., Jorgensen, C., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.037499 · Cited by 52
Miao, C., Huang, C., Huang, Y., Yang, Y., He, X., Zhang, L., Lv, X., Jin, Y. J., & Li, J. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.11.023 · Cited by 46
The role of innate lymphoid cells in health and disease
Mohammadi, H., Sharafkandi, N., Hemmatzadeh, M., Azizi, G., Karimi, M. H., Jadidi‐Niaragh, F., Baradaran, B., & Babaloo, Z. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26250 · Cited by 44
Self-citationAbatacept in the treatment of rheumatoid arthritis
Vital, E. M. J., & Emery, P. (2006) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2006.2.4.365 · Cited by 44
Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster
Yamaoka, K. (2016) · Drug Safety · doi:10.1007/s40264-016-0430-0 · Cited by 39
Efficacy of baricitinib in the treatment of rheumatoid arthritis
Richez, C., Truchetet, M., Kostine, M., Schaeverbeke, T., & Bannwarth, B. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1359256 · Cited by 39
Rezaei, R., Mahmoudi, M., Gharibdoost, F., Kavosi, H., Dashti, N., Imeni, V., Jamshidi, A., Aslani, S., Mostafaei, S., & Vodjgani, M. (2017) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13175 · Cited by 29
Self-citationAdalimumab for rheumatoid arthritis
Voulgari, P. V., & Drosos, A. A. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.12.1349 · Cited by 28
Kuusalo, L., Puolakka, K., Kautiainen, H., Blåfield, H., Eklund, K., Ilva, K., Kaipiainen‐Seppänen, O., Karjalainen, A. H., Korpela, M. M., Valleala, H., et al. (2015) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2015.1043142 · Cited by 24
Solomon, D. H., Lee, S. B., Zak, A., Corrigan, C., Agosti, J., Bitton, A., Harrold, L. R., Losina, E., Lü, B., Pincus, T., et al. (2016) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2016.02.009 · Cited by 22
A signal achievement in the treatment of arthritis
Cron, R. Q. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21206 · Cited by 21
Carlin, G., Djursäter, R., & SMEDEGÅRD, G. (1992) · Annals of the Rheumatic Diseases · doi:10.1136/ard.51.11.1230 · Cited by 21
Arthritis and Allied Conditions
Forrester-Brown, M. (1933) · BMJ · doi:10.1136/bmj.2.3782.32-a · Cited by 18
Symptom control with low-dose glucocorticoid therapy for rheumatoid arthritis
Kirwan, J., & Buttgereit, F. (2012) · Lara D. Veeken · doi:10.1093/rheumatology/kes085 · Cited by 15
Mohammadi, S., Mansouri, R., Shahi, A., Akhlaghi, M., Dashti, N., Aslani, S., Mansouri, M., Poursani, S., & Mahmoudi, M. (2018) · Meta Gene · doi:10.1016/j.mgene.2018.09.002 · Cited by 9
Self-citationZeng, H. M., & Li, T. (2016) · Fungal Genomics & Biology · doi:10.4172/2165-8056.1000132 · Cited by 8
Shigeyama (2000) · doi:10.1002/1529-0131(200011)43:11
Komuro (2001) · doi:10.1002/1529-0131(200112)44:12
Cited by
Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets
Wang, B., Wu, L., Chen, J., Dong, L., Chen, C., Wen, Z., Hu, J., Fleming, I., & Wang, D. W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00443-w · Cited by 1,414
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Lin, Y.-J., Anzaghe, M., & Schülke, S. (2020) · Cells · doi:10.3390/cells9040880 · Cited by 932
NF‐κB signaling in inflammation and cancer
Zhang, T., Ma, C., Zhang, Z., Zhang, H., & Hu, H. (2021) · MedComm · doi:10.1002/mco2.104 · Cited by 574
Macrophages: The Good, the Bad, and the Gluttony
Ross, E. A., Devitt, A., & Johnson, J. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708186 · Cited by 431
Epstein-Barr Virus and Systemic Autoimmune Diseases
Houen, G., & Trier, N. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.587380 · Cited by 379
Metadata
- Authors
- Abbasi, M., Mousavi, M. J., Jamalzehi, S., Alimohammadi, R., Bezvan, M. H., Mohammadi, H., & Aslani, S.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2018-12-07
- Volume
- 234
- Issue
- 7
- Pages
- 10018-10031
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2904023906
- Cited by
- 443
- References
- 146
- FWCI
- 24.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.